Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 75 years, of any gender
- People who have been diagnosed with non-small cell lung cancer (a type of lung cancer) confirmed through a tissue or cell sample, with a specific genetic change in the EGFR gene (either L858R or Exon19Del type)
- People who have been diagnosed with leptomeningeal metastasis (cancer that has spread to the fluid and membranes surrounding the brain and spinal cord), confirmed according to established international medical guidelines
- People whose cancer has continued to grow or spread after receiving double doses of a third-generation targeted therapy drug such as Osimertinib
- People with normal liver and kidney function, and blood counts within acceptable ranges (confirm with trial site for exact values)
- People with no history of severe nervous system disease
- People with no severe blood or bone marrow disorders
Who may not be able to join:
- People showing signs of serious nervous system failure, including severe brain dysfunction, significant white matter changes seen on brain scans, or a level of consciousness below a certain threshold (confirm with trial site)
- People who have widespread, life-threatening disease in other parts of the body that is not responding to treatment
- People who may have difficulty following the study requirements, or who have other reasons that make participation unsuitable as determined by the trial team
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhenyu Pan, Guangzhou Medical University
Phone: +8615804302753
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Clinical response rate; Neurological progression-free survival (NPFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.